KBU2046
KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life[1].
Product Specifications
CAS Number
1143863-69-7
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kbu2046.html
Purity
99.52
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1C(C2=CC=C(F)C=C2)COC3=CC=CC=C13
Molecular Formula
C15H11FO2
Molecular Weight
242.25
Precautions
H315, H319, H335
References & Citations
[1]Xu L, et al. Precision therapeutic targeting of human cancer cell motility. Nat Commun. 2018 Jun 22;9 (1) :2454.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
4-1BB Ligand (4-1BBL, 4-1BB-L, CD137L, CD157L, Homolog of Mouse 4-1BB-L, Homolog of Mouse 4-1BBL, ILA Ligand (TNF-related), Ly63L, Receptor 4-1BB Ligand, Tumor Necrosis Factor (Ligand) Superfamily Member 9) (MaxLight 405) discontinued
ALDH3B2 (Aldehyde Dehydrogenase Family 3 Member B2, Aldehyde Dehydrogenase 8, ALDH8) (MaxLight 650)